DK3383406T3 - Sammensætninger indeholdende decitabin, 5-azacytidin og tetrahydrouridin og anvendelser deraf - Google Patents

Sammensætninger indeholdende decitabin, 5-azacytidin og tetrahydrouridin og anvendelser deraf Download PDF

Info

Publication number
DK3383406T3
DK3383406T3 DK16871704.9T DK16871704T DK3383406T3 DK 3383406 T3 DK3383406 T3 DK 3383406T3 DK 16871704 T DK16871704 T DK 16871704T DK 3383406 T3 DK3383406 T3 DK 3383406T3
Authority
DK
Denmark
Prior art keywords
tetrahydrouridine
azacytidine
compositions containing
containing decitabine
decitabine
Prior art date
Application number
DK16871704.9T
Other languages
English (en)
Inventor
Yogen Saunthararajah
Joseph Desimone
Henry Lau
Santhosh Vadivelu
Original Assignee
Epidestiny Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epidestiny Inc filed Critical Epidestiny Inc
Application granted granted Critical
Publication of DK3383406T3 publication Critical patent/DK3383406T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK16871704.9T 2015-12-03 2016-12-05 Sammensætninger indeholdende decitabin, 5-azacytidin og tetrahydrouridin og anvendelser deraf DK3383406T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562262839P 2015-12-03 2015-12-03
US201662429292P 2016-12-02 2016-12-02
PCT/US2016/064935 WO2017096357A1 (en) 2015-12-03 2016-12-05 Compositions containing decitabine, 5azacytidine and tetrahydrouridine and uses thereof

Publications (1)

Publication Number Publication Date
DK3383406T3 true DK3383406T3 (da) 2022-01-10

Family

ID=58798100

Family Applications (2)

Application Number Title Priority Date Filing Date
DK16871704.9T DK3383406T3 (da) 2015-12-03 2016-12-05 Sammensætninger indeholdende decitabin, 5-azacytidin og tetrahydrouridin og anvendelser deraf
DK21203432.6T DK3960182T3 (da) 2015-12-03 2016-12-05 Sammensætninger indeholdende decitabin, 5-azacytidin og tetrahydrouridin samt anvendelser deraf

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK21203432.6T DK3960182T3 (da) 2015-12-03 2016-12-05 Sammensætninger indeholdende decitabin, 5-azacytidin og tetrahydrouridin samt anvendelser deraf

Country Status (9)

Country Link
US (3) US11376270B2 (da)
EP (2) EP3960182B1 (da)
JP (2) JP7194021B2 (da)
CN (1) CN109789155B (da)
BR (1) BR112018011324A2 (da)
CA (1) CA3007357C (da)
DK (2) DK3383406T3 (da)
MX (2) MX383757B (da)
WO (1) WO2017096357A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3976054B1 (en) * 2019-05-24 2026-01-07 The Cleveland Clinic Foundation Timed administration of decitabine and 5-azacytidine for cancer treatment
US20210077492A1 (en) * 2019-09-17 2021-03-18 The Trustees Of Indiana University Methods and compositions of treating pancreatic cancer
WO2021211890A1 (en) * 2020-04-16 2021-10-21 Adimabio Llc Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers
KR20240108406A (ko) 2021-10-19 2024-07-09 아키라바이오, 인크. 2'-데옥시시티딘 유사체를 포함하는 조성물 및 겸상 적혈구 질환, 지중해빈혈, 및 암의 치료를 위한 그의 용도

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5760208A (en) 1996-08-14 1998-06-02 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Process to prepare pyrimidine nucleosides
ATE339960T1 (de) 1999-03-01 2006-10-15 Halogenetics Inc Verwendung von zusammensetzungen enthaltend cldc als strahlungssensibilisatoren in der behandlung von neoplastischen erkrankungen
US6861513B2 (en) 2000-01-12 2005-03-01 Schering Corporation Everninomicin biosynthetic genes
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
US20050056280A1 (en) 2002-12-31 2005-03-17 Nektar Therapeutics Receptacle for an aerosolizable pharmaceutical formulation
US8158770B2 (en) 2004-05-06 2012-04-17 University Of Rochester Content dependent inhibitors of cytidine deaminases and uses thereof
US20060069060A1 (en) * 2004-09-27 2006-03-30 Sanjeev Redkar Salts of decitabine
US20060063735A1 (en) 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
US20060128653A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
US7601699B2 (en) 2005-08-01 2009-10-13 Nupotential, Inc. Production of reprogrammed cells with restored potential
UA99308C2 (ru) 2007-09-26 2012-08-10 Маунт Синай Скул Оф Медсин Аналог азацитидина и его применение
EP2050757A1 (en) * 2007-10-10 2009-04-22 Cilag AG Method of producing 2' -deoxy-5-azacytidine (Decitabine)
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
EP3782612B1 (en) 2008-05-15 2023-11-08 Celgene Corporation Oral formulations of cytidine analogs and methods of use thereof
US9265785B2 (en) * 2008-12-22 2016-02-23 The Board Of Trustees Of The University Of Illinois Compositions comprising decitabine and tetrahydrouridine and uses thereof
US9259469B2 (en) 2008-12-22 2016-02-16 The Board Of Trustees Of The University Of Illinois Compositions comprising decitabine and tetrahydrouridine and uses thereof
WO2010093435A1 (en) 2009-02-10 2010-08-19 Celgene International Sarl Methods for treating non-small cell lung cancer using 5-azacytidine
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
UY32546A (es) 2009-04-06 2010-10-29 Eisai Inc Composiciones y metodos para tratar cancer
AU2010234562B2 (en) 2009-04-06 2016-05-12 Taiho Pharmaceutical Co., Ltd. Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
CN102485232A (zh) * 2010-12-06 2012-06-06 苏州科耐尔医药科技有限公司 一种含地西他滨的药物组合物
WO2012106299A1 (en) * 2011-01-31 2012-08-09 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
US8426143B2 (en) * 2011-05-24 2013-04-23 Saladax Biomedical Inc. Gemcitabine immunoassay
US9476099B2 (en) 2012-08-10 2016-10-25 Trustees Of Dartmouth College Method for determining sensitivity to decitabine treatment
US20140100182A1 (en) 2012-10-05 2014-04-10 The Cleveland Clinic Foundation Nanogel-Mediated Drug Delivery
CA2906284A1 (en) 2013-03-15 2014-09-18 Epigenetics Pharma Llc Fluorinated pyrimidine analogs and methods of use thereof
WO2017158396A1 (en) 2016-03-16 2017-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Cytidine deaminase inhibitors for the treatment of pancreatic cancer

Also Published As

Publication number Publication date
DK3960182T3 (da) 2025-04-07
US11376270B2 (en) 2022-07-05
EP3383406B1 (en) 2021-10-20
JP7194021B2 (ja) 2022-12-21
JP2018538370A (ja) 2018-12-27
EP3383406A4 (en) 2019-08-21
CN109789155A (zh) 2019-05-21
MX383757B (es) 2025-03-04
BR112018011324A2 (pt) 2018-12-04
WO2017096357A1 (en) 2017-06-08
MX393043B (es) 2025-03-24
EP3960182A1 (en) 2022-03-02
EP3960182B1 (en) 2025-03-19
MX2021007569A (es) 2022-06-09
CA3007357C (en) 2023-12-05
US20200246368A1 (en) 2020-08-06
CN109789155B (zh) 2025-02-07
JP2022184941A (ja) 2022-12-13
CA3007357A1 (en) 2017-06-08
EP3383406A1 (en) 2018-10-10
US11779591B2 (en) 2023-10-10
US20220152075A1 (en) 2022-05-19
MX2018006790A (es) 2019-05-02
US20240165142A1 (en) 2024-05-23

Similar Documents

Publication Publication Date Title
IL273341A (en) Converted nucleosides, nucleotides and their analogs
DK3580561T3 (da) Hla-baserede metoder, sammensætninger og anvendelse heraf
DK3676297T3 (da) Forbindelser, sammensætninger og fremgangsmåder
ZA201704876B (en) Substituted nucleosides, nucleotides and analogs thereof
DK3407888T3 (da) Pyridopyrroloquinoxalinforbindelser, deres sammensætninger og anvendelser
IL249628A0 (en) Nucleosides, modified nucleotides and their analogs
IL249627A0 (en) Nucleosides, modified nucleotides and their analogs
MA46458A (fr) Compositions debacillus thuringiensis
IL251527B (en) Preparations of adenosine deaminase-2 (ada2), their variants and methods of using them
DK3475295T3 (da) Hidtil ukendt nukleosidtriphosphat-transportør og anvendelser deraf
DK3495023T3 (da) Semifluorerede forbindelser og sammensætninger deraf
EP3340805A4 (en) STEVIOL GLYCOSIDE MIXTURES, COMPOSITIONS AND METHOD
DK3424938T3 (da) 4'-azidoalkylsubstituterede nukleosider, nukleotider og analoger deraf
EP3297455A4 (en) GLYCOSIDZUSAMMENSETZUNGEN
EP3489306A4 (en) HEAT-CONDUCTIVE POLYORGANOSILOXAN COMPOSITION
DK3274430T3 (da) Mikroalgesammensætninger og deres anvendelser
BR112018000550A2 (pt) composição de glicosídeo de esteviol
IL263852B (en) Oligonucleotides comprising modified nucleosides
BR112018000298A2 (pt) composição de glicosídeo de esteviol
DK3383406T3 (da) Sammensætninger indeholdende decitabin, 5-azacytidin og tetrahydrouridin og anvendelser deraf
DK3383397T3 (da) Farmaceutiske sammensætninger indeholdende doravirin, tenofovirdisoproxilfumarat og lamivudin
CY2023020I1 (el) Συνθεσεις mycoplasma bovis
ITUB20152923A1 (it) Infisso ad elevata resistenza agli agenti atmosferici.
MA50025A (fr) Nucléosides de spirothiétane
MA45760A (fr) Bêta-naphthoisoflavones, compositions contenant celles-ci et leurs utilisations